Pradaxa (Dabigatran)
(prolonged in renal impairment)
(non-CYP)
Pellets: 20, 30, 40, 50, 110, 150 mg
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Stroke and systemic embolism prevention in non-valvular atrial fibrillation | Adults with non-valvular AF | Monotherapy | FDA Approved |
| Treatment of DVT and pulmonary embolism | Adults previously treated with parenteral anticoagulant for 5–10 days | Monotherapy (sequential) | FDA Approved |
| Reduction of risk of recurrent DVT/PE | Adults previously treated | Monotherapy (extended) | FDA Approved |
| VTE prophylaxis after total hip arthroplasty | Adults | Monotherapy (28–35 days) | FDA Approved |
| Treatment of VTE in pediatric patients | 3 months to <18 years (after ≥5 days parenteral therapy) | Monotherapy (sequential) | FDA Approved |
| Reduction of recurrent VTE in pediatric patients | 3 months to <18 years (previously treated) | Monotherapy (extended) | FDA Approved |
Dabigatran is the first oral direct thrombin inhibitor approved by the FDA and remains a core direct oral anticoagulant (DOAC) option for stroke prevention in non-valvular atrial fibrillation. Its predictable pharmacology eliminates the need for routine INR monitoring, and the availability of a specific reversal agent — idarucizumab — has been a major factor in clinician acceptance, particularly in patients facing urgent surgery or life-threatening bleeding. The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline and the 2024 ESC guideline both recommend DOACs (including dabigatran) over warfarin for most patients with NVAF, except those with mechanical heart valves or moderate-to-severe mitral stenosis.
The pediatric oral pellet formulation, approved by the FDA in June 2021, extended dabigatran’s role to children with VTE who can swallow soft food but not capsules. Dosage forms are not interchangeable on a milligram basis due to differences in bioavailability between the capsule and pellet formulations.
Cerebral venous sinus thrombosis (extended phase): The RE-SPECT CVT trial (n = 120) was an exploratory open-label study that found similar low rates of recurrent venous thromboembolism (none in either arm) and similar low rates of major bleeding with dabigatran 150 mg BID versus warfarin after 5–15 days of parenteral heparin. The trial was not powered for non-inferiority. Evidence quality: low.
Left ventricular thrombus: Some clinicians substitute dabigatran for warfarin based on small case series and observational registry data; randomized evidence is limited. Evidence quality: very low.
Bioprosthetic valve atrial fibrillation: Reasonable beyond the early postoperative period based on extrapolation from broader DOAC literature; dedicated dabigatran data are limited. Evidence quality: low.
Not recommended off-label: Mechanical heart valves (RE-ALIGN trial harm signal), moderate-to-severe mitral stenosis, triple-positive antiphospholipid syndrome, and pregnancy.
Dosing
Dosing is structured around the clinical scenario and creatinine clearance (Cockcroft-Gault). Capsules must be swallowed whole — opening or chewing the capsule increases dabigatran bioavailability by approximately 75% and substantially raises bleeding risk.
Adult Dosing by Clinical Scenario (Capsules)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Non-valvular AF — stroke prevention CrCl >30 mL/min | 150 mg PO BID | 150 mg PO BID | 300 mg/day | No loading dose; continue indefinitely while AF risk persists. Doses approximately 12 hours apart, with or without food. |
| Non-valvular AF CrCl 15–30 mL/min | 75 mg PO BID | 75 mg PO BID | 150 mg/day | US-only renal dose, derived from PK modelling (not direct trial data). Not recommended if CrCl <15 mL/min or on dialysis. |
| DVT/PE — acute treatment | 150 mg PO BID | 150 mg PO BID | 300 mg/day | Initiate after 5–10 days of parenteral anticoagulation (LMWH or UFH). Treatment duration usually 3–6 months. |
| DVT/PE — recurrence reduction | 150 mg PO BID | 150 mg PO BID | 300 mg/day | Begin after completing initial anticoagulation course. Reassess risk-benefit at 6–12 month intervals. |
| VTE prophylaxis after hip arthroplasty | 110 mg PO × 1 1–4 h after surgery, with hemostasis | 220 mg PO once daily | 220 mg/day | Continue for 28–35 days postoperatively. If hemostasis not achieved, defer until next day at 220 mg. |
Pediatric Dosing (Weight- and Age-Based)
| Age / Formulation | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| 3 months to <12 years (oral pellets) | Weight- and age-adjusted BID | Per weight band (PI Tables 2–3) | Mix with soft food (applesauce, mashed banana, mashed carrots) or apple juice — never with milk or dairy. Initiate after ≥5 days of parenteral anticoagulation for VTE treatment. | |
| 8 to <18 years (capsules) | Weight-based BID | 150 mg BID | Patient must be able to swallow capsules whole. Avoid in pediatric patients with eGFR <50 mL/min/1.73 m². | |
| <3 months | Not recommended | Renal function still maturing; alternatives preferred. | ||
Conversion Between Anticoagulants (Adults)
| Switch | How to Switch | Timing | Caution | Notes |
|---|---|---|---|---|
| Warfarin → Dabigatran | Stop warfarin; start dabigatran when INR <2.0 | — | — | No bridging needed. |
| Dabigatran → Warfarin | Begin warfarin; overlap timing depends on CrCl | CrCl ≥50: start warfarin 3 days before stopping dabigatran. CrCl 30–50: 2 days before. CrCl 15–30: 1 day before. | INR unreliable for ≥2 days after last dabigatran dose | Per FDA PI conversion section. |
| Parenteral → Dabigatran | Start dabigatran 0–2 h before next scheduled SC dose, or at time IV infusion stops | — | — | For LMWH/fondaparinux: at time of next scheduled dose. |
| Dabigatran → Parenteral | Start parenteral 12 h after last dabigatran dose (CrCl ≥30) | CrCl <30: 24 h gap | — | Avoid overlap to limit cumulative bleeding risk. |
Periprocedural Management
Per the FDA prescribing information, dabigatran should be discontinued 1–2 days before elective invasive or surgical procedures in patients with CrCl ≥50 mL/min, and 3–5 days before in patients with CrCl <50 mL/min. Consider longer interruption for major surgery, neuraxial procedures, or any setting where complete hemostasis is required. The EHRA Practical Guide on the use of DOACs offers more granular timing schemes stratified by both CrCl and procedural bleed risk that some clinicians prefer in complex cases. For pediatric patients on capsules, hold for 24 hours (eGFR >80 mL/min/1.73 m²) or 2 days (eGFR 50–80 mL/min/1.73 m²) before elective surgery.
The 110 mg BID dose is the standard NVAF dose in Europe and Canada for elderly or frail patients but is not approved by the FDA for stroke prevention in NVAF. Inside the US, the only renally adjusted NVAF dose is 75 mg BID for CrCl 15–30 mL/min, derived from pharmacokinetic modelling rather than direct trial data. Restart anticoagulation as soon as hemostasis is secured after any procedure — premature discontinuation is a major cause of breakthrough thromboembolism (boxed warning).
Pharmacology
Mechanism of Action
Dabigatran etexilate is an orally administered prodrug that is rapidly converted by plasma and hepatic esterases into dabigatran, a small-molecule competitive inhibitor of free and clot-bound thrombin (factor IIa). By blocking thrombin’s catalytic site, dabigatran prevents the cleavage of fibrinogen to fibrin, inhibits thrombin-mediated activation of factors V, VIII, XI, and XIII, and suppresses thrombin-induced platelet aggregation. The end result is interruption of the final common pathway of the coagulation cascade and reduction of thrombus formation in both venous and arterial circulation.
Unlike vitamin K antagonists, dabigatran produces a predictable, dose-related anticoagulant effect that does not require routine laboratory titration. Its effect can be rapidly reversed in adults by idarucizumab, a humanized monoclonal antibody fragment that binds dabigatran with very high affinity, restoring normal hemostasis within minutes of intravenous administration.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability 3–7%; Tmax ~1 h fasting; high-fat meal delays Tmax by ~2 h with no AUC effect; capsule contains a tartaric-acid pellet to lower local pH and aid dissolution | May be taken with or without food. Capsules must not be opened, broken, or chewed — bioavailability rises ~75% if the shell is removed, sharply increasing bleeding risk. |
| Distribution | Vd 50–70 L; protein binding ~35% | Low protein binding makes hemodialysis effective for emergency removal (~60% of drug removed over 2–3 hours). |
| Metabolism | Esterase-catalyzed hydrolysis of etexilate prodrug to active dabigatran; non-CYP; conjugation to pharmacologically active acyl glucuronides; the prodrug is a P-gp substrate | Few CYP-mediated drug interactions, but P-gp inhibitors and inducers significantly alter exposure. Hepatic CYP enzyme inducers/inhibitors are largely irrelevant. |
| Elimination | ~80% renal (unchanged drug); t½ ~12–14 h in healthy young/elderly volunteers, up to ~17 h in orthopaedic patients; markedly prolonged in renal impairment | Renal function is the dominant determinant of drug exposure. Reassess CrCl periodically and before any dose change. Not recommended for CrCl <15 mL/min or dialysis. |
The aPTT provides a qualitative estimate of dabigatran activity but is not titration-grade. The diluted thrombin time (dTT) and ecarin clotting time (ECT) correlate linearly with plasma concentration and are preferred when quantitative assessment is needed (e.g., urgent surgery, suspected toxicity). The INR is insensitive and unreliable for dabigatran. A normal thrombin time effectively rules out clinically relevant dabigatran activity.
Side Effects
Bleeding and gastrointestinal symptoms dominate the adverse-event profile. Frequencies below are derived from the RE-LY trial (NVAF, n = 18,113), the RE-COVER and RE-NOVATE programmes (VTE and orthopaedic prophylaxis), and FDA post-marketing surveillance.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dyspepsia / upper GI symptoms (NVAF) | 11.8% (110 mg) / 11.3% (150 mg) | Approximately twice the rate seen with warfarin (5.8%); driven in part by the tartaric-acid excipient. Often appears in the first 3 months and may resolve with food or PPI co-therapy. |
| Total gastrointestinal adverse reactions (NVAF) | 35% (150 mg) | Composite category in RE-LY versus 24% on warfarin; includes dyspepsia, abdominal pain, GERD-like symptoms, and gastritis-like symptoms. |
| Total gastrointestinal adverse reactions (post-hip prophylaxis) | 39.5% (220 mg) | Pooled RE-NOVATE I/II — same rate as enoxaparin 40 mg. |
| Any bleeding (NVAF, on-treatment, 150 mg) | 16.42%/yr | Composite of major plus minor bleeding (RE-LY); compares to 18.15%/yr on warfarin — overall bleeding lower than warfarin despite higher GI bleeding. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Major bleeding (any site, 150 mg) | 3.11%/yr | Versus warfarin 3.36%/yr — non-significant difference (RR 0.93, p = 0.31). Lower in patients <75 years; trend toward higher in those ≥75 years. |
| Major GI bleeding (150 mg) | 1.51%/yr | Significantly higher than warfarin (1.02%/yr, p < 0.001); risk concentrated in elderly and patients with prior peptic disease. |
| Major bleeding (hip prophylaxis, 220 mg) | 1.4–2.0% | RE-NOVATE I/II — slightly higher than enoxaparin 40 mg (1.6%/0.9%); rate of major GI bleeding 0.1%, same as enoxaparin. |
| Gastritis-like symptoms (RE-LY) | 2.1–2.5% | Includes GERD, esophagitis, gastric hemorrhage. Take with a full glass of water and remain upright ≥30 minutes to reduce esophageal mucosal contact. |
| Upper abdominal pain (RE-LY) | 2.8–3.0% | Versus 1.3% on warfarin. Often part of the broader dyspepsia complex. |
| Nausea, epistaxis, menorrhagia, anaemia (VTE indications) | ~1–5% | Reported as common drug-related adverse reactions in the FDA capsule label adult VTE pooled population. A new haemoglobin drop should prompt evaluation for occult GI bleeding rather than be attributed to drug alone. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Life-threatening bleeding (RE-LY, 150 mg) | 1.45%/yr | Any time | Stop drug; administer idarucizumab 5 g IV (in adults); supportive transfusion; consider hemodialysis if reversal unavailable. Versus warfarin 1.80%/yr. |
| Intracranial hemorrhage (RE-LY, 150 mg) | 0.30%/yr | Any time | Emergency neuroimaging; idarucizumab; reverse and consult neurosurgery. Approximately 40% of the rate seen with warfarin (0.74–0.76%/yr). |
| Hemorrhagic stroke (RE-LY, 150 mg) | 0.10%/yr | Any time | Same emergency response as ICH. Versus warfarin 0.38%/yr (p < 0.001). |
| Spinal / epidural hematoma (with neuraxial procedures) | Rare | Hours to days post-procedure | Urgent MRI; emergent neurosurgical decompression; reverse with idarucizumab in adults. Boxed warning — see Contraindications section. |
| Anaphylaxis / drug hypersensitivity | <0.1% | Within hours of dose | Stop permanently; epinephrine; emergency airway management. Includes urticaria, rash, pruritus, allergic edema, anaphylactic shock (RE-LY). |
| Agranulocytosis / neutropenia / thrombocytopenia | Very rare | Variable | CBC; discontinue if confirmed; hematology consult. Identified in FDA post-marketing reports. |
| Pill esophagitis (sloughing / exfoliative) | Uncertain | Days to weeks | Take with full glass of water; remain upright ≥30 min; stop drug and start PPI; switch DOAC if persistent. Single-centre endoscopy series have reported 9–21% prevalence among symptomatic dabigatran users undergoing endoscopy (Toya 2016; Tajima); true incidence in general practice unknown. |
| Premature discontinuation thrombosis (stroke, VTE recurrence) | Variable | Days after stopping | Bridge with alternative anticoagulant if planned interruption is >48–72 h and indication remains. Boxed warning — premature stop without coverage increases stroke and VTE risk. |
The FDA prescribing information identifies the principal triggers for stopping dabigatran in adults as bleeding and the gastrointestinal symptom complex. In the RE-LY GIS post-hoc analysis, approximately 4% of patients given dabigatran discontinued because of non-bleeding upper GI symptoms (most within the first 3 months), compared with 1.7% on warfarin. Switching to apixaban or rivaroxaban is reasonable when GI tolerability cannot be optimized despite food/PPI strategies.
Dyspepsia is the single most common reason for stopping dabigatran. Two strategies have evidence: (1) take each dose with a meal and a full glass of water; (2) co-prescribe a proton pump inhibitor (e.g., pantoprazole 40 mg daily). In the open-label GIS management trial, both strategies achieved partial or complete symptom resolution in roughly 60% of patients within 4 weeks. Switch to apixaban or rivaroxaban when symptoms persist despite both interventions.
Drug Interactions
Dabigatran is not metabolized by cytochrome P450, so interactions revolve almost entirely around P-glycoprotein (P-gp) transport at the intestinal mucosa, plus pharmacodynamic additivity with other agents that impair haemostasis. Renal function modifies the magnitude of every P-gp-mediated interaction — the lower the CrCl, the larger the change in exposure.
Monitoring
Routine coagulation testing is unnecessary. Monitoring focuses on renal function — the single most important parameter — plus bleeding surveillance and adherence.
-
CrCl / eGFR
Baseline; at least annually if normal; every 6 months if CrCl 30–60; every 3 months if CrCl <30; with any acute illness
Routine Use the Cockcroft-Gault equation (the formula used in clinical trials and for FDA labelling). Reduce or stop dose as renal function declines. Volume depletion, sepsis, or new contrast load can precipitate bleeding within days. -
Hemoglobin / hematocrit
Baseline; annually; sooner if symptoms
Routine A drop suggests occult bleeding — most often GI. Investigate before attributing to other causes. -
Liver enzymes (ALT, AST, bilirubin)
Baseline; annually
Routine Hepatotoxicity rates were similar to warfarin in RE-LY, but baseline values guide management of any future abnormality. -
Bleeding signs (clinical)
Every visit; patient self-monitoring
Routine Black or tarry stools, persistent epistaxis, gum bleeding, prolonged menstrual bleeding, easy bruising, headache or focal neurological symptoms. -
Adherence / refill timing
Every visit
Routine Short half-life means a single missed dose creates a real anticoagulation gap. Confirm refill cadence and bottle hygiene (4-month limit after opening). -
aPTT
Trigger only
Trigger-based Useful as a qualitative check before urgent surgery or in suspected toxicity. A normal aPTT does not exclude clinically meaningful drug effect. -
Diluted thrombin time / ECT
Trigger only
Trigger-based Quantitative assays for emergent settings — major bleeding, urgent surgery, suspected overdose. A normal thrombin time effectively rules out drug effect. -
Pregnancy testing
Trigger only
Trigger-based Confirm before initiating in patients of reproductive potential. Pregnancy on dabigatran requires immediate switch to LMWH. -
Stool occult blood / endoscopy
Trigger only
Trigger-based Pursue with any unexplained anemia or persistent dyspepsia, particularly in patients ≥75 years.
Contraindications & Cautions
Stopping any oral anticoagulant — including PRADAXA — without alternative coverage exposes the patient to stroke or recurrent VTE. If PRADAXA must be interrupted for reasons other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
Patients receiving neuraxial anaesthesia or undergoing spinal puncture while on PRADAXA are at risk of long-term or permanent paralysis from spinal or epidural haematoma. Risk is increased by indwelling epidural catheters, concomitant antithrombotic agents, traumatic or repeated procedures, and a history of spinal abnormalities or surgery. Time the procedure carefully relative to the last dose, monitor frequently for any neurological deficit, and obtain emergent imaging at the first sign of compression.
Absolute Contraindications
- Active pathological bleeding — any clinically significant ongoing haemorrhage.
- Serious hypersensitivity reaction — prior anaphylaxis or anaphylactic shock to dabigatran etexilate or excipients.
- Mechanical prosthetic heart valves — RE-ALIGN trial terminated early for excess thromboembolism and bleeding versus warfarin.
Relative Contraindications (Specialist Input Recommended)
- Triple-positive antiphospholipid syndrome — DOACs (including dabigatran) are not recommended; warfarin remains preferred.
- Severe renal impairment (CrCl <15 mL/min) or dialysis — no validated dose; switch to warfarin or LMWH.
- Moderate-to-severe mitral stenosis — DOAC efficacy not established; warfarin recommended.
- Pregnancy — limited human data; animal data show fetal harm; transition to LMWH.
- Recent intracranial / spinal surgery, recent stroke, or active intracranial lesion — defer initiation and re-stratify risk-benefit.
- Severe hepatic impairment (Child-Pugh C) — not studied; alternatives preferred.
Use with Caution
- Age ≥75 years — bleeding risk increases, particularly GI; consider whether 110 mg BID is available (outside US) or if apixaban is more appropriate.
- Body weight <50 kg or >120 kg — limited PK data at extremes; clinical judgement required.
- Concurrent P-gp inhibitors — adjust dose or avoid as outlined in interactions section.
- Recent / planned invasive procedure — follow periprocedural protocol stratified by CrCl and bleed risk.
- Active peptic ulcer disease or erosive esophagitis — co-prescribe a PPI; consider apixaban if recurrent GI bleeding.
- Concurrent NSAIDs, dual antiplatelet therapy, or SSRIs — reassess necessity, minimize duration, add gastroprotection.
Patient Counselling
Purpose of Therapy
Explain that dabigatran is a blood thinner that helps prevent dangerous clots from forming in the heart, lungs, or legs. The exact reason depends on the indication — for atrial fibrillation it lowers the chance of stroke, and for venous clots it stops new clots from forming while the body breaks down the existing one. Unlike warfarin, no routine blood tests are required, and there are no specific food restrictions.
How to Take
Take one capsule twice a day, about twelve hours apart, with or without food. Swallow capsules whole — never break, chew, or open them, since this dramatically increases bleeding risk. Keep capsules in their original sealed bottle or blister pack until use; the desiccant inside the bottle protects them from moisture. If using a bottle, discard any unused capsules four months after the bottle is first opened. Capsules in unopened blister packs remain good until the printed expiry date. Do not transfer capsules to a pill organizer. If a dose is missed and the next dose is more than 6 hours away, take it as soon as remembered; otherwise skip it. Never double up.
Sources
- Boehringer Ingelheim Pharmaceuticals. Pradaxa (dabigatran etexilate) Capsules — US Prescribing Information. accessdata.fda.gov/drugsatfda_docs/label/2024/022512s047lbl.pdf Source for adult indications, dosing tables, contraindications, and pivotal-trial adverse-event tables cited throughout the monograph.
- Boehringer Ingelheim Pharmaceuticals. Pradaxa Oral Pellets — US Prescribing Information. accessdata.fda.gov/drugsatfda_docs/label/2025/214358s009lbl.pdf Authoritative source for pediatric dosing, oral pellet formulation, and DIVERSITY trial labelling.
- European Medicines Agency. Pradaxa Summary of Product Characteristics. ema.europa.eu/en/medicines/human/EPAR/pradaxa European licensing reference; the 110 mg BID NVAF dose available in Europe is not approved by the FDA.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med 2009;361:1139–51. doi.org/10.1056/NEJMoa0905561 Pivotal stroke prevention trial — basis for FDA approval and the 150 mg BID NVAF dose; source of major bleeding (3.11%/yr) and ICH (0.30%/yr) figures.
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER). N Engl J Med 2009;361:2342–52. doi.org/10.1056/NEJMoa0906598 Established non-inferiority of dabigatran 150 mg BID versus warfarin for VTE treatment after parenteral lead-in.
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN). N Engl J Med 2013;369:1206–14. doi.org/10.1056/NEJMoa1300615 Trial terminated early for harm — basis for the absolute contraindication in mechanical-valve patients.
- Halton J, Brandão LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021;8:e22–e33. doi.org/10.1016/S2352-3026(20)30368-9 Pediatric pivotal trial supporting the oral pellet and weight-based capsule dosing schemes.
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis (RE-VERSE AD). N Engl J Med 2017;377:431–441. doi.org/10.1056/NEJMoa1707278 Defined the role of idarucizumab in life-threatening bleeding and emergency surgery.
- Ferro JM, Coutinho JM, Dentali F, et al; RE-SPECT CVT Study Group. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019;76(12):1457–1465. doi.org/10.1001/jamaneurol.2019.2764 Exploratory open-label trial of dabigatran versus warfarin after CVT (n = 120); informs the limited off-label evidence for this setting.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation 2024;149(1):e1–e156. doi.org/10.1161/CIR.0000000000001193 Current US recommendation that DOACs (including dabigatran) are preferred over warfarin in eligible NVAF patients.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2024;45(36):3314–3414. doi.org/10.1093/eurheartj/ehae176 European recommendation supporting DOACs over vitamin K antagonists, with cautions for triple-positive APS, mechanical valves, and moderate-to-severe mitral stenosis.
- Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021;160(6):e545–e608. doi.org/10.1016/j.chest.2021.07.055 Reference for VTE treatment duration and DOAC sequencing after parenteral therapy.
- Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47(5):285–95. doi.org/10.2165/00003088-200847050-00001 Foundational pharmacology paper covering esterase activation, P-gp transport, and dose-proportional kinetics.
- Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61(25):2495–502. doi.org/10.1016/j.jacc.2013.02.058 Detailed review of the P-gp interaction landscape that underpins dabigatran’s drug-interaction profile.
- Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial. J Am Coll Cardiol 2014;63(4):321–8. doi.org/10.1016/j.jacc.2013.07.104 Plasma-concentration analysis showing how renal function and age drive bleeding risk — basis for individualized dosing considerations.
- Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013;11(3):246–52. doi.org/10.1016/j.cgh.2012.10.021 Granular characterization of dyspepsia incidence (16.9% vs 9.4% on warfarin) and discontinuation patterns (~4% on dabigatran).
- Bouget J, Balusson F, Maignan M, et al. Major bleeding risk associated with oral anticoagulant in real clinical practice: a multicentre 3-year period population-based prospective cohort study. Br J Clin Pharmacol 2020;86(12):2519–2529. doi.org/10.1111/bcp.14362 Real-world French cohort comparing major bleeding risk across DOACs and VKAs — informs cautions on age, renal function, and concomitant antithrombotics.
- Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43(6):1511–7. doi.org/10.1161/STROKEAHA.112.650614 Source for intracranial hemorrhage rates by site and outcome in the RE-LY population.